[{"x_label":"Diffuse hemispheric glioma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 28)","specimen_descriptor_fill":"Pediatric Primary and Relapse Tumors","box_sample_count":28,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Diffuse hemispheric glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":19.21,"TPM_sd":15.69,"TPM_min":5.18,"TPM_25th_percentile":8.78,"TPM_median":13.11,"TPM_75th_percentile":22.22,"TPM_max":66.85},{"x_label":"Colon Adenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 289)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":289,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Colon Adenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1001949","MONDO":"MONDO_0002271","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.67,"TPM_sd":2.29,"TPM_min":1.3,"TPM_25th_percentile":2.62,"TPM_median":3.23,"TPM_75th_percentile":4.18,"TPM_max":23.09},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":165,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.2,"TPM_sd":1.68,"TPM_min":0.85,"TPM_25th_percentile":3.02,"TPM_median":4.05,"TPM_75th_percentile":4.97,"TPM_max":12.09},{"x_label":"Hepatocellular Carcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 371)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":371,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Hepatocellular Carcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000182","MONDO":"MONDO_0007256","GTEx_tissue_subgroup_UBERON":"","TPM_mean":2.17,"TPM_sd":1.21,"TPM_min":0.44,"TPM_25th_percentile":1.29,"TPM_median":1.9,"TPM_75th_percentile":2.75,"TPM_max":8.36},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":521,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.56,"TPM_sd":1.98,"TPM_min":1.41,"TPM_25th_percentile":4.14,"TPM_median":5.34,"TPM_75th_percentile":6.69,"TPM_max":13.23},{"x_label":"Lung Adenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 512)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":512,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Lung Adenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000571","MONDO":"MONDO_0005061","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.02,"TPM_sd":2.86,"TPM_min":0.7,"TPM_25th_percentile":3.44,"TPM_median":4.36,"TPM_75th_percentile":5.93,"TPM_max":36.96},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":378,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.23,"TPM_sd":1.58,"TPM_min":1.1,"TPM_25th_percentile":3.18,"TPM_median":4.04,"TPM_75th_percentile":5.01,"TPM_max":11.23},{"x_label":"Rectum Adenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 93)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":93,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Rectum Adenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0005631","MONDO":"MONDO_0002169","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.63,"TPM_sd":1.17,"TPM_min":0.92,"TPM_25th_percentile":2.81,"TPM_median":3.44,"TPM_75th_percentile":4.33,"TPM_max":6.54},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":261,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.43,"TPM_sd":2.18,"TPM_min":1.08,"TPM_25th_percentile":2.91,"TPM_median":4.12,"TPM_75th_percentile":5.45,"TPM_max":19.22},{"x_label":"Uterine Corpus Endometrial Carcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 179)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":179,"Gene_Ensembl_ID":"ENSG00000157764","Gene_symbol":"BRAF","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Uterine Corpus Endometrial Carcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0007532","MONDO":"MONDO_0000553","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.41,"TPM_sd":4.37,"TPM_min":0.58,"TPM_25th_percentile":2.7,"TPM_median":3.8,"TPM_75th_percentile":4.96,"TPM_max":44.36}]